Evolent Health (EVH) holders disclose 1,713 shares, under 5% ownership

Rhea-AI Filing Summary

Evolent Health, Inc. received an amended ownership report from Eventide Asset Management, LLC and individuals Finny Kuruvilla and Robin C. John. They report beneficial ownership of 1,713 shares of Class A common stock, representing 0.0% of the class as of 12/31/2025.

Eventide holds sole voting and dispositive power over the 1,713 shares, while Kuruvilla and John share voting and dispositive power over the same shares. The securities are certified as acquired and held in the ordinary course of business and not for the purpose of influencing control of Evolent Health.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 01:22 PM Learn about SEC filing dates

FAQ

What stake in Evolent Health (EVH) does Eventide Asset Management report?

Eventide Asset Management reports beneficial ownership of 1,713 shares of Evolent Health Class A common stock. This represents 0.0% of the outstanding class, indicating only a very small position relative to total shares.

Who are the reporting persons in this Evolent Health (EVH) Schedule 13G/A?

The reporting persons are Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph.D., and Robin C. John. They file jointly regarding their beneficial ownership of Evolent Health Class A common stock, with a joint filing agreement included as an exhibit.

How is voting and dispositive power over Evolent Health (EVH) shares allocated?

Eventide has sole voting and sole dispositive power over 1,713 shares. Kuruvilla and John each have shared voting and shared dispositive power over the same 1,713 shares, with no sole voting or dispositive authority individually.

Does this Evolent Health (EVH) filing indicate ownership above 5%?

No. The filing explicitly states ownership of 5 percent or less of the class. The reported 1,713 shares correspond to 0.0% of Evolent Health’s Class A common stock, confirming the position is well below the 5% threshold.

Why are Eventide and its principals filing an amended Schedule 13G/A for Evolent Health (EVH)?

They are reporting their current beneficial ownership position as of December 31, 2025. The certification states the securities were acquired and are held in the ordinary course of business, not to change or influence control of Evolent Health.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

Evolent Health, Inc.

(Name of Issuer)

Class A Common Stock, par value $0.01 per share

(Title of Class of Securities)

30050B101

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 30050B101

1

Names of Reporting Persons

Eventide Asset Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,713.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,713.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,713.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 30050B101

1

Names of Reporting Persons

Finny Kuruvilla, M.D. Ph. D.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,713.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,713.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,713.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP No. 30050B101

1

Names of Reporting Persons

Robin C. John

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,713.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,713.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,713.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Evolent Health, Inc.
(b)	Address of issuer's principal executive offices: 1812 North Moore St, Suite 1705, Arlington, VA, 22209
Item 2.
(a)	Name of person filing: (i) Eventide Asset Management, LLC ("Eventide") (ii) Finny Kuruvilla, M.D., Ph.D. ("Kuruvilla") (iii) Robin C. John ("John")
(b)	Address or principal business office or, if none, residence: Eventide, Kuruvilla and John: One International Place, Suite 4210 Boston, Massachusetts 02110
(c)	Citizenship: Eventide: Delaware Kuruvilla: United States John: United States
(d)	Title of class of securities: Class A Common Stock, par value $0.01 per share
(e)	CUSIP No.: 30050B101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: (i) Eventide: 1,713 (ii) Kuruvilla: 1,713 (iii) John: 1,713
(b)	Percent of class: (i) Eventide: 0.0% (ii) Kuruvilla: 0.0% (iii) John: 0.0%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: (1) Eventide: 1,713 (2) Kuruvilla: 0 (3) John: 0
	(ii) Shared power to vote or to direct the vote: (1) Eventide: 0 (2) Kuruvilla: 1,713 (3) John: 1,713
	(iii) Sole power to dispose or to direct the disposition of: (1) Eventide: 1,713 (2) Kuruvilla: 0 (3) John: 0
	(iv) Shared power to dispose or to direct the disposition of: (1) Eventide: 0 (2) Kuruvilla: 1,713 (3) John: 1,713
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Eventide Asset Management, LLC

Signature:	/s/ Peter J. Luiso
Name/Title:	Peter J. Luiso, General Counsel
Date:	02/13/2026

Finny Kuruvilla, M.D. Ph. D.

Signature:	/s/ Finny Kuruvilla, M.D., Ph. D.
Name/Title:	Finny Kuruvilla, M.D., Ph. D.
Date:	02/13/2026

Robin C. John

Signature:	/s/ Robin C. John
Name/Title:	Robin C. John
Date:	02/13/2026

Exhibit Information

EXHIBIT 1 WHEREAS, in accordance with Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934 (the "Act"), only one joint Statement and any amendments thereto need to be filed whenever one or more persons are required to file such a Statement or any amendments thereto pursuant to Section 13(d) of the Act with respect to the same securities, provided that said persons agree in writing that such Statement or amendments thereto is filed on behalf of each of them; NOW, THEREFORE, the parties hereto agree as follows: Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph. D. and Robin C. John do hereby agree, in accordance with Rule 13d-1(k)(1) under the Act, to file a Statement on Schedule 13G relating to their ownership of the Common Stock of the Issuer, and do hereby further agree that said Statement on Schedule 13G shall be filed on behalf of each of them. Eventide Asset Management, LLC Date: February 13, 2026 By: /s/ Peter J. Luiso Name: Peter J. Luiso Title: General Counsel Date: February 13, 2026 Finny Kuruvilla, M.D., Ph. D. By: /s/ Finny Kuruvilla, M.D., Ph. D. Name: Finny Kuruvilla, M.D., Ph. D. Date: February 13, 2026 Robin C. John By: /s/ Robin C. John Name: Robin C. John